Abstract 1851P
Background
We have previously reported on the initial results of the prospective longitudinal PICO-SM study (Lim et al. 2023), highlighting the impact of the COVID-19 pandemic on the lives of patients with colorectal cancer. Herein, we present the psychological impact of the third wave of the pandemic to patients, when the Omicron variant became prevalent (December 2021 to early 2022).
Methods
Patients were invited to participate in cohort II of the PICO-SM study by completing a questionnaire, including screening psychometric tools. Multivariate analysis was performed using logistic regression for binary outcomes: anxiety (GAD-7 score ≥ 5), depression (PHQ-9 score ≥ 10), and poor well-being (WHO-5 < 50); and odds ratios (OR) with 95% confidence interval (CI) were calculated.
Results
In total, 96 participants were included: mean age 64 years, 64% (n = 61) males. 33% (n = 32/96) reported poor well-being (WHO-5 < 50), 27% (n = 26/96) anxiety (GAD-7 ≥ 5), 11% (n = 11/96) depressive symptoms (PHQ-9 ≥ 10) and 3% (n = 3/96) probable post-traumatic stress disorder (PC-PTSD-5 ≥ 4). The results compare with distress levels in the second pandemic wave: 31%, 24%, 15% and 3%, respectively. Multivariate analysis showed that patients who had investigations cancelled (OR 9.22, 95% CI 1.09-77.85; p = 0.041) or felt that the pandemic would affect their mental health (OR 3.82, 95% CI 1.96-7.44; p < 0.001) had increased risk of anxiety. Similarly, concern that the pandemic would affect their cancer treatment (OR 4.59, 95% CI 1.03-20.56; p = 0.046) or would affect their mental health (OR 3.90, 95% CI 1.38-11.03; p = 0.010) were found independent predictors of poor wellbeing.
Conclusions
The psychological distress experienced by patients, particularly anxiety, remained persistently high during the third wave of the COVID-19 pandemic. These updated results align with our initial findings, emphasizing the critical importance of continuing cancer treatment amidst the ongoing humanitarian emergency. It is crucial for healthcare services to prioritize ongoing psychological support for cancer patients, with a particular focus on those who are more vulnerable.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Servier.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1878P - Prevalence of burnout in GU oncologists in central Asia: BUCARE survey
Presenter: Oxana Shatkovskaya
Session: Poster session 05
1879P - Investigating the effect of family support on the mental health of patients with breast cancer
Presenter: Maryam Garousi
Session: Poster session 05
1880P - Cancer care: Psychoeducational intervention for first-year residents of a general hospital in northeastern Mexico
Presenter: Celia Beatriz Gonzalez-Alcorta
Session: Poster session 05
1991P - Safety and effectiveness of surgery or radiotherapy after PD-L1 Inhibitor (TQB-2450) and chemotherapy induction therapy in patients with limited-stage small cell lung cancer: A phase II trial
Presenter: Fenghuan Sun
Session: Poster session 05
1992P - A phase II safety and efficacy study of PM8002 (anti-PD-L1 x VEGF-A bispecific) combined with paclitaxel as a second-line therapy for small cell lung cancer (SCLC)
Presenter: Ying Cheng
Session: Poster session 05
1993P - Phase IIIb study of durvalumab plus platinum–etoposide in first-line treatment of extensive-stage small cell lung cancer (CANTABRICO): Safety results
Presenter: Maria Dolores Isla Casado
Session: Poster session 05
1994P - Carboplatin, etoposide, bevacizumab, and atezolizumab in patients with extensive-stage SCLC – GOIRC-01-2019 CeLEBrATE ML41241 trial
Presenter: Karim Rihawi
Session: Poster session 05
1995P - Long-term benefit of atezolizumab plus chemotherapy in extensive stage small cell lung cancer (ES-SCLC): Exploratory analysis from the IMfirst study
Presenter: Maria Rosario Garcia Campelo
Session: Poster session 05
1996P - The impact of an etoposide shortage on patients with extensive-stage small cell lung cancer (ES-SCLC): Results of a natural experiment
Presenter: Claire Browne
Session: Poster session 05
1997P - A study of sintilimab combined with anlotinib and chemotherapy as second-line or later therapy in extensive-disease small cell lung cancer
Presenter: Zhe-Hai Wang
Session: Poster session 05